MFG
LGND icon

Mendota Financial Group’s Ligand Pharmaceuticals LGND Stock Holding History

Mendota Financial Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1
Closed -$101 – 817
2024
Q3 		$101 Buy
+1
New +$101 ﹤0.01% 928

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mendota Financial Group's LGND Position: Q4 2024 in Review

Mendota Financial Group sold out of Ligand Pharmaceuticals (LGND) in Q4 2024, closing a stake of 1 share — an estimated $101 sold.

Mendota Financial Group first reported a position in LGND in Q3 2024 and held it in 1 quarter. The position peaked at $101 in Q3 2024. 258 funds tracked by Wall St. Rank hold LGND as of Q4 2024.

  • Mendota Financial Group reported no remaining Ligand Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Mendota Financial Group sold 1 Ligand Pharmaceuticals share in Q4 2024, an estimated $101.
  • Mendota Financial Group first reported a position in Ligand Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Mendota Financial Group's Ligand Pharmaceuticals position peaked at $101 in Q3 2024.
  • 258 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2024.

Based on Mendota Financial Group's 13F filing for Q4 2024, filed 14 Jan 2025.